Lead drug from Janux to join wave of new prostate cancer treatments | $JANX
Wines taste better with age. Men supposedly age better than women. Yet when it comes to prostate cancer, the risk for men does not improve with age. For men less than age 50, only 1 in 350 are diagnosed with prostate cancer. Between 50 and 59, the diagnosis rate increases to 1 out of 52. And after age 65, the figure astonishingly rises to nearly 6 out of 10.
Not surprisingly, drug developers always are on high alert for new prostate cancer treatments. The rebound of precision radiopharmaceuticals started with the introduction of Novartis’ (NYSE:NVE) Pluvicto to treat prostate cancer. Two private radiopharmaceutical companies advanced similar prostate cancer treatments and were acquired by Big Pharma for multiple billions.
Janux Therapeutics, Inc. (NASDAQ:JANX) targets prostate cancer, and other cancers, via its Tumor Activated T-cell Engager (TRACTr) platform. The company’s phase Ia clinical trial delivered stellar data in February 2024. In one cohort, the drug JANX007 was tested in 18 patients diagnosed with late-stage metastatic castration-resistant prostate cancer (mCPRC). Ten of 18 (56%) experienced prostate specific antigen (PSA) declines of PSA50 after the first dose of the drug JANX007 at ≥ 0.1mg. Janux plans to update its JANX007 phase I trial in the second half of 2024.
Key catalysts
Phase I interim data update for JANX007 to treat metastatic castration-resistant prostate cancer (mCPRC)
Key catalyst dates
2H 2024
—
